Chia Tai Tianqing Ramelteon Tablets Submitted Clinical Drug Application to Grab Takeda's Blockbuster New Drug

Recently, Nanjing Chia Tai Tianqing Pharmaceutical submitted its first drug clinical application this year.
Ramelteon is an oral hypnotic drug developed by Takeda of Japan
.

Figure 1: The latest products declared by Nanjing Chia Tai Tianqing

Source: CDE official website

According to the data, ramelteon is the first melatonin receptor agonist used in clinical treatment of insomnia, and it is also the first and so far the only prescription drug for insomnia without abuse and dependence.
It is mainly used for the treatment of insomnia that is difficult to fall asleep.
It also has definite curative effect on chronic insomnia and short-term insomnia
.

According to the data from Minet.
com, Japan's Takeda submitted a clinical application for the import of ramelteon tablets in 2007 and obtained the clinical approval, but has not yet declared for import and marketing
.

Figure 2: Domestic clinical situation of ramelteon

Source: new version database of Minet

Wuhan Changlian Laifu Pharmaceutical/Wuhan Xianlu Pharmaceutical Technology carried out the bioequivalence test of ramelteon tablets in 2019.

Table 1: Products declared by Nanjing Chia Tai Tianqing in 2021

Source: MED2.

The R&D strength of Nanjing Chia Tai Tianqing cannot be ignored either.